# T-CELL RECRUITMENT ENGINEERING: MD ANDERSON INFOGRAPHIC BLUEPRINT

**Document Type:** Visual Pitch Deck  
**Format:** 7-slide deck  
**Audience:** Dr. Kristen Pauken Lab, MD Anderson Leadership  
**Purpose:** Email-ready visual summary for partnership proposal

---

## **DESIGN PRINCIPLES**

**Tone:** Collaborative, hypothesis-driven, mutual value  
**Visual Hierarchy:** Discovery â†’ Problem â†’ Solution â†’ Pilot â†’ Value  
**Color Palette:**  
- MD Anderson Red (#C8102E) for their discoveries  
- CrisPRO Blue (#0052CC) for our solutions  
- Gradient overlay where they intersect (partnership)

**Key Message:** "You measure recruitment. We diagnose WHY it failsâ€”and design the rescue."

---

## **SLIDE 1: THE FOUNDATION â€“ DR. PAUKEN'S BREAKTHROUGH**

### **Header:**
**"The IV Timestamp: Measuring T-Cell Recruitment in Real-Time"**

### **Visual:**
```
[LEFT HALF - MD Anderson Discovery]
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ IV Antibody Injection          â”‚
â”‚                                â”‚
â”‚ Blood â†’ Tissue Migration       â”‚
â”‚ Tracked Over 24-72h            â”‚
â”‚                                â”‚
â”‚ âœ… IV+ = Fresh Recruits        â”‚
â”‚    (Less exhausted)            â”‚
â”‚                                â”‚
â”‚ âœ… IV- = Residents             â”‚
â”‚    (More exhausted)            â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

[RIGHT HALF - Key Findings]
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Finding #1: Fresh recruits     â”‚
â”‚ are FITTER (LOW PD-1/TIM-3)    â”‚
â”‚                                â”‚
â”‚ Finding #2: Recruitment        â”‚
â”‚ collapses over time            â”‚
â”‚ (Day 10 HIGH â†’ Day 25 LOW)     â”‚
â”‚                                â”‚
â”‚ Finding #3: Anti-PD-1 DOUBLES  â”‚
â”‚ recruitment (logistics drug)   â”‚
â”‚                                â”‚
â”‚ Finding #4: Same highways for  â”‚
â”‚ cancer & autoimmunity          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### **Footer:**
> **"First tool in the world to track T-cell recruitment in real-time. Game-changing for both cancer immunotherapy and autoimmunity research."**

---

## **SLIDE 2: THE PROBLEM â€“ 70% FAILURE RATE**

### **Header:**
**"The $50B Question: Why Do Checkpoint Inhibitors Fail?"**

### **Visual:**
```
[CENTER - Large Circle Diagram]

        70-80% FAIL
    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
    â”‚                 â”‚
    â”‚   âŒ âŒ âŒ âŒ   â”‚
    â”‚   âŒ âŒ âŒ âŒ   â”‚  â† Late-stage tumors
    â”‚   âŒ âŒ âŒ âŒ   â”‚    Recruitment COLLAPSED
    â”‚                 â”‚
    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
           â†“
    The Grand Challenge:
    
    â“ WHY does recruitment collapse?
       â€¢ Chemokines lost?
       â€¢ Physical barriers?
       â€¢ Vascular collapse?
       â€¢ Suppressor cells?
    
    â“ WHICH tumors need WHICH intervention?
    
    â“ CAN we rescue collapsed recruitment?
```

### **Footer:**
> **"$35B wasted annually on non-responders. Dr. Pauken can MEASURE the collapse. But doesn't know WHY. Can't design precision rescue without diagnosis."**

---

## **SLIDE 3: THE SOLUTION â€“ BOTTLENECK DIAGNOSTIC**

### **Header:**
**"From Measurement to Engineering: RNA-Seq â†’ Bottleneck â†’ Intervention"**

### **Visual:**
```
[WORKFLOW DIAGRAM]

Step 1: DIAGNOSE                    Step 2: DESIGN
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  Tumor RNA-Seq   â”‚â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€>   â”‚ Precision Rescue â”‚
â”‚  + Timestamp     â”‚                â”‚  (4 Solutions)   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
         â”‚                                   â”‚
         â†“                                   â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Type A: Chemokine Desert â†’ Overexpression Cassetteâ”‚
â”‚ Type B: Physical Barrier â†’ Stromal Remodeling     â”‚
â”‚ Type C: Suppressor       â†’ Anti-TGFÎ²/VEGF         â”‚
â”‚ Type D: Vascular Collapseâ†’ VEGF Normalization     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

Confidence:
â€¢ Type A/C designs: âœ… HIGH (validated tools)
â€¢ Type B/D designs: âš ï¸ MEDIUM (requires testing)
â€¢ RNA-seq â†’ bottleneck: âš ï¸ MEDIUM (r = 0.3-0.5 lit baseline)
```

### **Footer:**
> **"Not one solutionâ€”FOUR. Different tumors need different interventions. Bottleneck classifier tells you WHICH to use."**

### **ğŸš¨ Critical Note:**
**Hypothesis-Driven:** 8-week pilot TESTS if RNA-seq predicts bottlenecks (target: r > 0.60). If bulk fails, pivot to spatial RNA-seq.

---

## **SLIDE 4: REALITY CHECK â€“ WHAT WE'RE TESTING**

### **Header:**
**"Validated Capabilities vs. Untested Assumptions"**

### **Visual:**
```
[TWO-COLUMN LAYOUT]

âœ… VALIDATED (HIGH CONFIDENCE)          âš ï¸ TESTING (REQUIRES YOUR DATA)
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€       â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
â€¢ Evo2 API (sequence design)           â€¢ Bulk RNA â†’ bottleneck prediction
â€¢ CRISPRi guide design                   Hypothesis: r > 0.60 achievable
â€¢ RNA-seq analysis pipelines             Literature: r = 0.3-0.5
â€¢ Off-target search (GRCh38)             
â€¢ Antibody design tools                â€¢ Bottleneck rescue â†’ recruitment
â€¢ Recruitment biology (peer-reviewed)    Hypothesis: Fixing bottleneck
                                         increases IV+ influx >2X
                                         
                                       â€¢ Selective autoimmunity blockade
                                         Hypothesis: Tissue-specific or
                                         timing-based selectivity possible

â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€       â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
ğŸ¯ Operational Now                     ğŸ¯ 8-Week Pilot Tests These
```

### **Footer:**
> **"We're NOT claiming we have the answer. We're proposing to TEST our hypotheses with YOUR gold-standard timestamp data. If assumptions fail, we pivot (spatial RNA-seq, combination designs) or document non-druggable bottlenecks."**

---

## **SLIDE 5: THE 8-WEEK PILOT â€“ PROVE IT**

### **Header:**
**"$0 Cost. 30 Samples. 8 Weeks. Co-Author If It Works."**

### **Visual:**
```
[TIMELINE DIAGRAM]

WEEK 1-2: Data Transfer
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ MD Anderson Provides:           â”‚
â”‚ â€¢ 20-30 tumors (HIGH/LOW recr.) â”‚
â”‚ â€¢ Bulk RNA-seq                  â”‚
â”‚ â€¢ Timestamp flow (IV+ counts)   â”‚
â”‚ â€¢ Clinical metadata             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

WEEK 3-4: Bottleneck Classification (HYPOTHESIS TEST)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ â€¢ Correlation: genes vs IV+     â”‚
â”‚ â€¢ Train classifier: Type A/B/C/Dâ”‚
â”‚                                 â”‚
â”‚ Hypothesis: r > 0.60 achievable â”‚
â”‚ (Literature baseline: r=0.3-0.5)â”‚
â”‚                                 â”‚
â”‚ âœ… Success: r > 0.60 â†’ HIGH confâ”‚
â”‚ âš ï¸ Caution: r = 0.50-0.60       â”‚
â”‚ ğŸ”„ Pivot: r < 0.50 â†’ spatial    â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

WEEK 5-6: Intervention Design
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ â€¢ 5 designs (one per bottleneck)â”‚
â”‚ â€¢ Off-target, immunogenicity    â”‚
â”‚ â€¢ Validation protocols          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

WEEK 7-8: Deliverables Package
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ 1. Bottleneck heatmap (30 tmrs) â”‚
â”‚ 2. Gene signature (top 20)      â”‚
â”‚ 3. Anti-PD-1 response predictor â”‚
â”‚ 4. 5 intervention designs       â”‚
â”‚ 5. Calibration report (r-value) â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### **Footer:**
**IF ASSUMPTIONS FAIL - PIVOT PLAN:**
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ â€¢ RNA r < 0.50 â†’ Spatial RNA-seq (add 2-4 months) â”‚
â”‚ â€¢ Multiple bottlenecks â†’ Combination designs      â”‚
â”‚ â€¢ Rescue fails â†’ ID non-druggable, stratify       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Cost: $0. Exit anytime. You keep all code/designs if it fails.**

---

## **SLIDE 6: THE VALUE PROPOSITION**

### **Header:**
**"What MD Anderson Gets"**

### **Visual:**
```
[THREE BOXES]

BOX 1: DIAGNOSTIC TOOL               BOX 2: THERAPEUTIC DESIGNS
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”        â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ â€¢ Pre-treatment biomarkerâ”‚        â”‚ â€¢ 4 precision cassettes  â”‚
â”‚   (who responds to PD-1?)â”‚        â”‚   (patient-specific)     â”‚
â”‚                          â”‚        â”‚                          â”‚
â”‚ â€¢ Bottleneck classifier  â”‚        â”‚ â€¢ Validation protocols   â”‚
â”‚   (enrich clinical trials)â”‚       â”‚   (de-risk experiments)  â”‚
â”‚                          â”‚        â”‚                          â”‚
â”‚ â€¢ $500/sample OR         â”‚        â”‚ â€¢ 3-5% royalty on        â”‚
â”‚   $50K institutional     â”‚        â”‚   licensed products      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜        â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

BOX 3: PUBLICATIONS & IP
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ â€¢ Co-author Nature Immun â”‚
â”‚   (bottleneck classifier)â”‚
â”‚                          â”‚
â”‚ â€¢ Co-author Nat Med      â”‚
â”‚   (intervention trials)  â”‚
â”‚                          â”‚
â”‚ â€¢ Joint IP (70/30 split) â”‚
â”‚   MD Anderson 70%        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### **Footer:**
> **"This partnership creates tools NO competitor can replicate. Your timestamp data trains proprietary models. Data moat + learning system = sustainable advantage."**

---

## **SLIDE 7: WHY MD ANDERSON? WHY NOW?**

### **Header:**
**"Strategic Timing: Capture The Data Advantage"**

### **Visual:**
```
[THREE URGENCY PILLARS]

âœ… YOUR DISCOVERY IS NOVEL            â° CHECKPOINT MARKET IS SATURATED
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€         â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
Timestamp tool published 2023-24     Generic PD-1 flooding market
                                     
First-mover advantage for            Need combination products to
building classifier                  differentiate
                                     
Capture data moat NOW before         Recruitment enhancer + PD-1 =
others catch up                      next-gen therapy


â° PATIENT NEED IS IMMEDIATE          ğŸ¯ PARTNERSHIP FLYWHEEL
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€         â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
70% checkpoint patients fail         Your timestamp â†’ trains our model
                                     
Every 8-week delay = lost            Our designs â†’ your validation
patients                             
                                     Your outcomes â†’ improve our tools
$35B wasted annually on              
non-responders                       Learning loop = compound advantage
```

### **Footer:**
> **"The opportunity window is NOW. Your timestamp tool is unique. Your data trains proprietary algorithms. This partnership positions MD Anderson as the T-cell recruitment engineering leaderâ€”and turns measurement into medicine."**

---

## **PRESENTATION SCRIPT (2-MINUTE VERSION)**

**SLIDE 1:**
> "Dr. Pauken, your IV timestamp tool is the first method in the world to track T-cell recruitment in real-time. You've proven fresh recruits are fitter, recruitment collapses over time, and anti-PD-1's primary mechanism is DOUBLING fresh T-cell influxâ€”not just waking up exhausted cells."

**SLIDE 2:**
> "But 70-80% of checkpoint patients still fail. You can MEASURE recruitment collapseâ€”but you don't know WHY. Is it chemokines? Physical barriers? Vascular collapse? Suppressors? Without diagnosis, you can't design the RIGHT rescue."

**SLIDE 3:**
> "CrisPRO offers a Bottleneck Diagnostic. Give us your RNA-seq + timestamp data, and we'll classify tumors into 4 typesâ€”then design precision interventions. Type A gets chemokine overexpression. Type B gets stromal remodeling. Type C gets suppressor neutralization. Type D gets vascular normalization. Not one solutionâ€”FOUR."

**SLIDE 4:**
> "Full transparency: We're TESTING this. Our design tools are validatedâ€”but we don't know if bulk RNA-seq can predict your timestamp measurements. Literature baseline is r = 0.3-0.5. We're betting we can hit r > 0.60 with your gold-standard data. If we fail, we pivot to spatial RNA-seqâ€”or document what DOESN'T work. Either way, you get designs + code."

**SLIDE 5:**
> "The pilot is 8 weeks, $0 cost, 30 samples. Week 1-2: data transfer. Week 3-4: train classifier, test if RNA predicts bottlenecks. Week 5-6: design 5 interventions. Week 7-8: deliver heatmap, gene signature, anti-PD-1 predictor, designs, validation protocols. If r > 0.60, we publish together. If r < 0.50, we recommend spatial and you keep everything."

**SLIDE 6:**
> "What you get: A pre-treatment biomarker to enrich clinical trials. Four precision therapeutic designs. Co-authorship on Nature Immunology and Nature Medicine papers. Joint IP with 70/30 split. And a learning systemâ€”your validation experiments improve our models, compounding your advantage."

**SLIDE 7:**
> "Why now? Your timestamp discovery is novelâ€”this is your window to capture the data moat before others build competing classifiers. The checkpoint market is saturatedâ€”combination products are the differentiator. And 70% of patients are failingâ€”every 8-week delay costs lives. This partnership turns your measurement breakthrough into medicine."

---

## **EMAIL-READY SUMMARY (PASTE INTO MESSAGE)**

**Subject:** Partnership Proposal: T-Cell Recruitment Engineering (MD Anderson + CrisPRO)

**Body:**

Dr. Pauken,

Your IV timestamp tool is the first method to track T-cell recruitment in real-time. You've proven recruitment collapses (Day 10 â†’ Day 25) and that anti-PD-1 DOUBLES fresh T-cell influx. This is breakthrough science.

**The Gap:** You can MEASURE recruitment collapseâ€”but don't know WHY (chemokines? barriers? vessels? suppressors?). Without diagnosis, can't design precision rescue.

**Our Proposal:** 8-week pilot, $0 cost, 30 tumors (RNA-seq + timestamp data)
- **DIAGNOSE:** RNA-seq â†’ bottleneck classification (Type A/B/C/D)
- **DESIGN:** 4 precision interventions (one per bottleneck type)
- **PREDICT:** Anti-PD-1 response biomarker (pre-treatment)

**Deliverables:**
1. Bottleneck heatmap for all 30 tumors
2. Gene signature (top 20 genes predicting recruitment collapse)
3. 5 intervention designs with validation protocols
4. Calibration report (r-value, performance metrics)

**Hypothesis:** Bulk RNA-seq predicts bottlenecks (target: r > 0.60; lit baseline: r = 0.3-0.5)  
**Pivot Plan:** If r < 0.50, recommend spatial RNA-seq and re-train

**Cost:** $0. Co-author + co-own IP if it works. You keep everything if it fails.

**Value:** De-risk your next 3 years of experiments. Turn measurement into medicine.

Attached: 7-slide visual deck outlining pilot, deliverables, and partnership terms.

Can we schedule 60 minutes to discuss?

Best,  
[Your Name]  
CrisPRO.ai

---

**INFOGRAPHIC STATUS:** ğŸŸ¢ **EMAIL-READY**  
**Format:** 7 slides, 2-min script, email summary included  
**Tone:** Collaborative, hypothesis-driven, transparent about unknowns
